Please login to the form below

Not currently logged in
Email:
Password:

Pearl Therapeutics

This page shows the latest Pearl Therapeutics news and features for those working in and with pharma, biotech and healthcare.

Daily Brief: AstraZeneca's new San Fran home, Keytruda triumphs again, Novo branches out

Daily Brief: AstraZeneca's new San Fran home, Keytruda triumphs again, Novo branches out

The state-of-the-art labs bring together researchers from four parts of the AZ family – the 2013-acquired Pearl Therapeutics, 2015- acquired Acerta Pharma, plus MedImmune, and AstraZeneca’s TIDE

Latest news

More from news
Approximately 1 fully matching, plus 11 partially matching documents found.

Latest Intelligence

  • Deal Watch table for June 2013 Deal Watch table for June 2013

    2, 150. Pearl Therapeutics / AstraZeneca. Acquisition. Inhaled small molecules including PT003 fixed dose combination (LABA/ LAMA for COPD (phase III).

  • Pharma deals during June 2013 Pharma deals during June 2013

    Respiratory acquisitions. Continuing its run of deal activities, AstraZeneca (AZ) built on its respiratory interests with the acquisition of Pearl Therapeutics at a headline value of $1.15bn. ... AZ paid an initial $560m for Pearl's shares and a deferred

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

  • Kala names Howard Rosen as chairman Kala names Howard Rosen as chairman

    He is former CEO of Pearl Therapeutics and VP at Gilead. ... His non-board experience includes serving as president and CEO of Pearl Therapeutics, which was acquired by AstraZeneca last year in a deal worth up to $1.15bn, as well as

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
certain health

Transforming the way health brands and companies communicate, we deliver creative science led, insight-driven solutions that give award winning results...

Latest intelligence

How can we strike the right balance between familiarity and innovation when it comes to data presentation?
Following our webinar in March, Getting MedComms right: navigating the age of the amateur expert, we’re taking the time to respond to questions we were unable to answer during the...
Deep 6 AI: the smart software breathing new life into clinical trials
Fishawack Health interviews Wout Brusselaers, the Deep 6 AI CEO using artificial intelligence to solve one of the greatest barriers stagnating healthcare innovation—clinical trial recruitment and retention....
COVID-proof: How Teams are Creating Launch Intensity thru Adversity
Now that the game has changed, how are marketers shifting their launch behaviour? We've identified 5 common observations from effective teams....